Methoxy polyethylene glycol-epoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease

Drugs

Volumn 68, Issue 8, 2008, Pages 1139-1156

  Curran, Monique P ^a,b   McCormack, Paul L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Anaemia, treatment; Epoetin beta, general; Kidney disorders

Indexed keywords

HEMOGLOBIN; MACROGOL; METHOXY POLYETHYLENE GLYCOL EPOETIN BETA; MIRCERA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; PHARMACODYNAMICS; RETICULOCYTE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

ANEMIA; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY DISEASES; POLYETHYLENE GLYCOLS;

EID: 43749117511     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00009     Document Type: Review

References (66)

1. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 May; 19 Suppl. 2: ii1-47
2. National Kidney Foundation - Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006 May; 47 (5 Suppl. 3): S11-145
3. Macdougall IC, Eckardt K-U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006 Sep 9; 368 (9539): 947-53
4. F. Hoffmann-La Roche Ltd. Summary of product characteristics: MIRCERA (methoxy polyethylene glycol-epoetin beta) [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-739-PI-en.pdf [Accessed 2008 Mar 14]
5. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006 Nov; 1 (6): 1211-5
6. Jarsch M, Brandt M, Lanzendörfer M, et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-β determined by surface plasmon resonance and competition binding assay. Pharmacology 2008 Sep 28; 81 (1): 63-9
7. Jarsch M, Kubbies M, Lanzendörfer M, et al. C.E.R.A. acts differently at the erythropoietin (EPO) receptor compared with epoetin beta: UT-7 and CD34+ cell stimulation assays [abstract no. SA-PO209]. 39th Annual Meeting and Scientific Exhibition of the American Society of Nephrology: Renal Week; 2006 Nov 14-19; San Diego (CA)
8. Tare N, Pill J, Haselbeck A. Preclinical pharmacodynamics and pharmacokinetics of CERA (continuous erythropoiesis receptor activator): a new erythropoietic agent for anaemia management in patients with kidney disease [abstract no. M526]. 41st Congress of the European Renal Association and the European Dialysis and Transplant Association; 2004 May 15-18; Lisbon
9. Tillmann HC, Kuhn B, Kränzlin B, et al. Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 2006 Jan; 69 (1): 60-7
10. Reigner B, Jordan P, Pannier A, et al. CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent: dose-dependent response in phase I studies [abstract no. 2943]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL)
11. Fishbane S, Pannier A, Liogier X, et al. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycolepoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007 Nov; 47 (11): 1390-7
12. Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007; 16 (10): 1649-61
13. European Medicines Association. Scientific discussion: summary of product characteristics: MIRCERA (methoxy polyethylene glycol-epoetin beta) [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-739- en6.pdf [Accessed 2008 Apr 20]
14. Dougherty FC, Reigner B, Jordan P, et al. CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics, and tolerability in phase I multiple ascending dose studies. Support Oncol 2005; 3 (2 Suppl. 1): 10-1
15. Hoffmann-La Roche Inc. Full prescribing information (US): Mircera® (methoxy polyethylene glycol-epoetin beta). Nutley (NJ): Hoffmann-La Roche Inc., 2007
16. de Francisco ALM, Sulowicz W, Klinger M, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006 Dec; 60 (12): 1687-96
17. Besarab A, Salifu MO, Lunde NM, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 2007 Apr; 29 (4): 626-39
18. Locatelli F, Villa G, de Francisco ALM, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007 May; 23 (5): 969-79
19. Provenzano R, Besarab A, Macdougall IC, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007 May; 67 (5): 306-17
20. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene-glycol epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50 (6): 989-1000
21. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3 (2): 337-47
22. Levin NW, Fishbane S, Cañedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007 Oct 20; 370 (9596): 1415-21
23. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007 Jul; 2 (4): 637-46
24. Canaud B, Braun J, Locatelli F, et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin levels in patients with chronic kidney disease on dialysis [abstract no. SP425]. Nephrol Dial Transplant 2006 Jul; 21: iv157
25. Spinowitz B, Coyne DW, Lok CE, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008; 28: 280-9
26. Data on file. Hoffmann-La Roche Ltd., 2008
27. Saueressig U, Sapède C, De Cock E, et al. Staff time and costs for anaemia management with erythropoietic stimulating agents in patients on haemodialysis [abstract no. SaP341]. Nephrol Dial Transplant 2007; 22 Suppl. 6: V1347-8
28. Pannier A, Jordan P, Dougherty FC, et al. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. Curr Med Res Opin 2007 Oct 24; 23 (12): 3025-32
29. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ 2006; 332: 563-4.
30. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365 (9456): 331-40
31. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2007 Annual Data Report. Am J Kidney Dis 2008; 51: S1-320.
32. European Renal Association - European Dialysis and Transplant Association. ERA-EDTA Registry Annual Report 2005 [online]. Available from URL: http://www.era.edta-reg.org [Accessed 2008 Jan 8]
33. National Kidney Foundation - Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1-266
34. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162 (12): 1401-8
35. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20 (9): 1501-10
36. Gouva C, Nikolopoulos P, Ioannidis JPA, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66 (2): 753-60
37. Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005; 101: c79-86
38. Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65: 757-67
39. National Kidney Foundation - Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50 (3): 471-530
40. National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease [online]. Available from URL: http://www.nice.org.uk/guidance/cg39/niceguidance/pdf/English [Accessed 2008 Mar 14]
41. Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006; 45 (5): 503-10
42. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. Biodrugs 2005; 19 (5): 327-43
43. Amgen Europe B.V. Darbepoetin alfa (Aranesp® ): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/aranesp/H-33 2-PI-en.pdf [Accessed 2008 Mar 3]
44. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-12
45. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5
46. Fishbane S, Besarab A. Mechanism of increased mortality with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-82
47. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007 Feb 3; 369 (9559): 381-8
48. Ishani A, Solid CA, Weinhandl ED, et al. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008 May; 23 (5): 1682-9
49. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006 Apr; 17 (4): 1181-91
50. Gilbertson DE, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2007 Nov; 3: 133-8
51. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98
52. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84
53. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-12
54. Tefferi A. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor? Mayo Clin Proc 2007 Nov; 82 (11): 1316-8
55. Strippoli GFM, Tognoni G, Navaneethan SD, et al. Haemoglobin targets: we were wrong, time to move on. Lancet 2007 Feb 3; 369 (9559): 346-50
56. National Kidney Foundation. Preliminary anemia guideline update: new evidence spurs re-examination of 2006 recommendations [online]. Available from URL: http://www.kidneyorg/news/newsroom/newsitem.cfm?id=380 [Accessed 2008 March 26]
57. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-43
58. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD; an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46 (3): 481-8
59. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-21
60. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007 Nov; 82 (11): 1371-80
61. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351 (14): 1403-8
62. U.S. Food and Drug Administration. Communication about an ongoing safety review: erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procite Epogen) darbepoetin alfa (marketed as Aranesp) [online]. Available from URL: http://www.fda.gov/cder/drug/early_comm/ESA.htm [Accessed 2008 Jan 7]
63. Roche. Recruitment temporarily suspended into C.E.R.A. phase II oncology trial [online]. Available from URL: http://roche.com/med-cor-2007-02-23c [Accessed 2008 Jan 7]
64. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003; 18 Suppl. 2: ii2-6
65. London R, Solis A, Goldberg GA, et al. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002; 40 (3): 539-48
66. Maddux FW, Shetty S, del Aquila MA, et al. Effect of erythropoiesis- stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 2007; 41 (11): 1761-9